Model-Based Meta-Analysis (MBMA) vs. Meta-Analysis – Why Traditional Meta-Analysis Alone Isn’t Enough

Meta-analysis summarizes existing trial results—but it often falls short for forecasting, dose–response modeling, or trial simulation. Model-Based Meta-Analysis (MBMA) adds dimensions of dose, time, and variability, unlocking deeper insights and more reliable predictions.

What You’ll Learn

✔️ Key differences between traditional meta-analysis and MBMA
✔️ Where MBMA adds the most value in drug development
✔️ Real-world scenarios where MBMA supports regulatory and trial decisions

Real-World Impact

See how MBMA has helped drug developers reduce trial costs, refine dose selection, and build stronger submissions.

Best Practices

Learn practical steps for planning, modeling, and aligning MBMA strategies with regulatory expectations.

MBMA is redefining evidence synthesis in drug development.

Download the guide to see how it can elevate your decision-making and strengthen development programs.